<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eightk.txt
<TEXT>


                          UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C. 20549


                            FORM 8-K

                        Current Report
               Pursuant to Section 13 or 15(d) of
              the Securities Exchange Act of 1934


      Date of Report (Date of earliest event reported):
                       April 18, 2007


                        JOHNSON & JOHNSON

     (Exact name of registrant as specified in its charter)


    New Jersey       1-3215          22-1024240

(State or other    Commission    (I.R.S. Employer
jurisdiction       File Number)  Identification No.)
of incorporation)


 One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

           (Address of principal executive offices)
                          (zip code)

Registrant's telephone number including area code:
                       (732) 524-0400

Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)


Item 2.02 Results of Operations and Financial Condition

On  April  17,  2007, the Company issued supplemental  tables  of
sales  of key products/franchises to its press release announcing
the  Company's  sales  and earnings for the first  quarter  ended
April  1,  2007.   These tables appear in Exhibit  99.1  to  this
report  and  are incorporated  herein by reference.  In  addition,
the  press release reported operational sales growth rates  on  a
pro  forma basis to include the net impact of the acquisition  of
Pfizer  Consumer Healthcare.  A presentation of these  pro  forma
operational  sales  rates  and the  as reported operational sales
growth  rates  appears  in  Exhibit  99.2  to  this report and is
incorporated herein by reference.


Item 7.01 Regulation FD Disclosure.

On  April  17,  2007,  during  the first  quarter  2007  earnings
conference call with the investment community, the Company raised
2007 full year adjusted earnings per share guidance to a range of
$4.02-$4.07*.    This  guidance  reflects  the  Company's   solid
financial  performance in the first quarter  of  2007,  continued
cost  control  and the impact from its financing  strategy.   The
guidance includes the impact of the dilutive effect, excluding in-
process  research  &  development, of the  acquisition  of  Conor
Medsystems,  Inc.,  which was completed in  February  2007.   The
Company  also  increased guidance for 2007 full year  operational
sales growth to between 12.0% and 12.5%.

*Adjusted earning per share excludes in-process research and
development charges, as well as other special items.

(This report contains "forward-looking statements" as defined  in
the  Private  Securities Litigation Reform  Act  of  1995.  These
statements are based on current expectations of future events. If
underlying  assumptions  prove inaccurate  or  unknown  risks  or
uncertainties  materialize, actual results could vary  materially
from Johnson & Johnson's expectations and projections. Risks  and
uncertainties    include   general   industry   conditions    and
competition;  economic  conditions, such  as  interest  rate  and
currency  exchange rate fluctuations; technological advances  and
patents  attained  by  competitors; challenges  inherent  in  new
product  development,  including obtaining regulatory  approvals;
domestic  and  foreign health care reforms and governmental  laws
and  regulations; and trends toward health care cost containment.
A  further list and description of these risks, uncertainties and
other  factors can be found in Exhibit 99 of the Company's Annual
Report on Form 10-K for the fiscal year ended December 31,  2006.
Copies  of  this  Form 10-K, as well as subsequent  filings,  are
available  online  at www.sec.gov or on request  from  Johnson  &
Johnson.  Johnson  &  Johnson does not undertake  to  update  any
forward-looking  statements as a result  of  new  information  or
future events or developments.)


Item 9.01 Financial Statements and Exhibits

Exhibit No.    Description

99.1      Sales of Key Products/Franchises 1Q 2007

99.2      Presentation of Pro Forma Operational Sales Growth Rates



                            SIGNATURE

Pursuant  to the requirements of the Securities Exchange  Act  of
1934, the registrant has duly caused this report to be signed  on
its behalf by the undersigned hereunto duly authorized.


                              JOHNSON & JOHNSON
                              (Registrant)


Date: April 18, 2007         By: /s/ Stephen J. Cosgrove
                                 Stephen J. Cosgrove
                                 Controller
                                 (Principal Accounting Officer)


</TEXT>
</DOCUMENT>